Objectives: By developing the deep learning model SPE-YOLO, the detection of small pulmonary embolism has been improved, leading to more accurate identification of this condition. This advancement aims to better serve medical diagnosis and treatment.
Methods: This retrospective study analyzed images of 142 patients from Tianjin Medical University General Hospital using YOLOv8 as the foundational framework. Firstly, a small detection head P2 was added to better capture and identify small targets. Secondly, the SEAttention mechanism was integrated into the model to enhance focus on crucial features and optimize detection accuracy. Lastly, the feature extraction process was refined by introducing ODConv convolution to capture more comprehensive contextual information, thereby enhancing the detection performance of small pulmonary embolisms. The model's practical application ability was evaluated using 2000 cases from the RSNA dataset as an external test set.
Results: In the Tianjin test set, our model achieved a precision of 84.20 % and an accuracy of 81.50 %. This represents an improvement of approximately 5 % and 4 % respectively compared to the original YOLOv8. F1 scores, recall rates and average accuracy have also increased by 4 %, 5 %, 6 %, respectively. In data from the external validation set of RSNA, SPE-YOLO exhibited its effectiveness with a sensitivity of 90.70 % and an accuracy of 86.45 %.
Conclusion: The SPE-YOLO algorithm demonstrates strong capability in identifying small pulmonary embolisms, offering clinicians a more accurate and efficient diagnostic tool. This advancement is expected to enhance the quality of pulmonary embolism diagnosis and support the progress of medical services.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.compbiomed.2024.109402 | DOI Listing |
Respir Res
December 2024
National Jewish Health, Denver, USA.
Background: We sought consensus among practising respiratory physicians on the prediction, identification and monitoring of progression in patients with fibrosing interstitial lung disease (ILD) using a modified Delphi process.
Methods: Following a literature review, statements on the prediction, identification and monitoring of progression of ILD were developed by a panel of physicians with specialist expertise. Practising respiratory physicians were sent a survey asking them to indicate their level of agreement with these statements on a binary scale or 7-point Likert scale (- 3 to 3), or to select answers from a list.
BMC Neurosci
December 2024
Powell Mansfield, Inc., San Diego, CA, USA.
Obstructive sleep apnea (OSA) is widespread, under-recognized, and under-treated, impacting the health and quality of life for millions. The current gold standard for sleep apnea testing is based on the in-lab sleep study, which is costly, cumbersome, not readily available and represents a well-known roadblock to managing this huge societal burden. Assessment of neuromuscular function involved in the upper airway using electromyography (EMG) has shown potential to characterize and diagnose sleep apnea, while the development of transmembranous electromyography (tmEMG), a painless surface probe, has made this opportunity practical and highly feasible.
View Article and Find Full Text PDFVirchows Arch
December 2024
Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Université Côte d'Azur, CHU Nice, FHU OncoAge, IHU RespirERA, Nice, France.
EGFR status assessment is mandatory for adjuvant decision-making of resected stage IB-IIIA non-squamous non-small cell lung cancer (NS-NSCLC). It is questionable whether single-gene RT-PCR versus next-generation sequencing (NGS) should be used for this evaluation. Moreover, co-occurring mutations have an impact on tumor behavior and may influence future therapeutic decision-making.
View Article and Find Full Text PDFCancer Sci
December 2024
Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is the standard therapy for patients harboring T790M after first-generation EGFR-TKI resistance. However, the impact of acquired EGFR amplification on the efficacy of third-generation EGFR-TKI against T790M remains uncertain. We aimed to investigate whether the presence of acquired EGFR amplification after first-generation EGFR-TKI resistance influences the efficacy of third-generation EGFR-TKI in patients with advanced non-small-cell lung cancer (NSCLC).
View Article and Find Full Text PDFSci Bull (Beijing)
December 2024
Thoracic Oncology Institute & Research Unit of Intelligence Diagnosis and Treatment in Early Non-small Cell Lung Cancer, Chinese Academy of Medical Sciences, 2021RU002, Peking University People's Hospital, Beijing 100044, China; Department of Thoracic Surgery, Peking University People's Hospital, Beijing, China; Institute of Advanced Clinical Medicine, Peking University, Beijing 100191, China. Electronic address:
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!